PeopleGary has worked in the pharmaceutical industry for over 30 years, starting as a bench scientist and progressing to Director of Drug Metabolism and Pharmacokinetics in Psychiatry, Respiratory & inflammatory, and Immuno-inflammatory disease areas within Drug Discovery at GSK.
Gary has been involved in the development of several key medicines including Ventolin, Zantac and Serevent and progressed 35 new compounds into early and late stage development. He has also led cross-discipline research and development teams within cardiovascular and psychiatric disease areas.
Gary gained his PhD in 1995 studying species differences in drug metabolism and went on to collaborate with the University of Dundee to crystallise a major human phenolsulphotransferase enzyme. Gary is the co-author on 26 published papers.